Daré Bioscience (NASDAQ:DARE) Share Price Crosses Below Two Hundred Day Moving Average – What’s Next?

Daré Bioscience, Inc. (NASDAQ:DARE) passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $3.42 and traded as low as $3.08. Daré Bioscience shares last traded at $3.08, with a volume of 29,956 shares.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Daré Bioscience in a research note on Tuesday, December 17th.

Daré Bioscience Stock Performance

The company has a market cap of $26.80 million, a PE ratio of -5.21 and a beta of 1.32. The stock’s 50-day simple moving average is $3.24 and its 200 day simple moving average is $3.42.

Institutional Investors Weigh In On Daré Bioscience

A hedge fund recently raised its stake in Daré Bioscience stock. Renaissance Technologies LLC grew its holdings in Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 778,700 shares of the biotechnology company’s stock after buying an additional 15,800 shares during the quarter. Renaissance Technologies LLC owned about 9.25% of Daré Bioscience worth $262,000 at the end of the most recent quarter. 6.70% of the stock is owned by hedge funds and other institutional investors.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.